Clinical Trials Directory

Trials / Completed

CompletedNCT03803241

Cd133+ Cell Infusion in Patients With Colorectal Liver Metastases.

Cd133+ Cell Infusion in Patients With Colorectal Liver Metastases That Are Going to be Submitted to a Major Liver Resection

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
4 (actual)
Sponsor
Hospital San Carlos, Madrid · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

Treatment of patients with metastatic colorectal carcinoma is surgical resection. Only 10-15% of the patients will be candidates for curative resection. After response to chemotherapy this figure rises 10-13% more. To perform the surgery it is necessary to have a sufficient remnant liver volume (RLV), which allows maintaining optimal liver function after resection. If the estimated RLV is insufficient preoperatively, portal venous embolization site (PVE) is performed for compensatory hypertrophy, thus increasing the number of resections 19%. Still, in 20% of these patients surgery can not be performed because RLV is not achieved or because the disease progresses while waiting for growth. Therefore, it is necessary to improve liver regeneration without promoting tumor growth. Studies on liver regeneration, have determined that cells (CD133 +) are involved in the liver hypertrophy that occurs after hepatectomy. CD133 + have been used to induce liver hypertrophy with encouraging results. This population of CD133 +, can be selected from peripheral blood after stimulation with Granulocyte colony-stimulating factor (G-CSF), being able to obtain a large number of them. The investigators propose to treat patients who do not meet criteria for surgery because of insufficient volume \<40%, with CD133 + and portal embolization in order to carry out a surgical resection in a second place.

Conditions

Interventions

TypeNameDescription
DRUGCD133+ infusionInfusion of cells cd133+
OTHERportal vein embolizationportal vein embolization

Timeline

Start date
2019-05-31
Primary completion
2020-12-31
Completion
2021-06-30
First posted
2019-01-14
Last updated
2021-09-27

Locations

2 sites across 1 country: Spain

Source: ClinicalTrials.gov record NCT03803241. Inclusion in this directory is not an endorsement.